Disturbances in the hemostatic system of patients with endogenous hypercorticism and metabolic syndrome

Close metadata

Recommended articles:

Efficacy and safety of a new selective oral factor Xa inhibitor amidine hydrochloride for the prevention of thromboembolic events in hospitalized patients with COVID-19. Results of a multicenter, prospective, randomized, controlled study. Journal of Venous Disorders. 2024;(2):154-162

Predictors of effective complex physiotherapy in patients with skin involution. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(1):13-20

Efficacy and Safety of a New Selective Oral Factor Xa Inhibitor Amidine Hydrochloride for Prevention of Thromboembolic Events in Hospitalized Patients with COVID-19: a Multiple-Center Prospective Randomized Controlled Study. Journal of Venous Disorders. 2024;(2):154-162

Serum uric acid — a metabolic marker of non-alcoholic fatty liver disease. Russian Journal of Evidence-Based Gastroenterology. 2024;(2):36-42

Assessment of the condition of organs and tissues of the oral cavity in people with dentition defects against the background of metabolic syndrome. Stomatology. 2024;(3):31-38

A personalized application of therapeutic physical factors in patients with metabolic syndrome. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(2):5-11

Skin alterations as possible clinical markers of diabetes mellitus and metabolic syndrome. Russian Journal of Preventive Medicine. 2024;(7):101-107

Cognitive impairments and emotional disorders and their correction in perimenopausal women. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):48-53

Forensic characteristic of sudden death cases in subjects with metabolic syndrome. Forensic Medical Expertise. 2024;(4):54-57

Effect of blue range light-emitting diode radiation on platelets and blood coagulation factors in patients with chronic ischemia of lower limbs. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(4):9-15

Long-standing hypercortisolemia is accompanied by multiple defects of metabolic regulation. Glucocorticoids are known to affect not only metabolic processes but also the vascular wall directly influencing its remodeling and angiogenesis. Syndrome of endogenous hypercorticism is characterized by various disturbances in the hemostatic system and a tendency toward the development of hypercoagulation. Altered metabolic and hemostatic parameters in the active phase of the disease persist during a long time after the achievement of remission. It accounts for the high risk of atherosclerosis, atherothrombosis, and thromboembolic complications which necessitates correction with medicinal preparations throughout the follow-up period. According to foreign authors, thromboembolic complications are the main cause of mortality among the patients with this clinical condition and occur 4 times as frequently as in the general population.

Keywords:

hypercorticism

metabolic syndrome

hemostasis

thromboembolic complications

Authors:

Khodakova Iu.V.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Arapova S.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Sukhanova G.A.

Gematologicheskiĭ nauchnyĭ tsentr, Moskva

Chirkova L.D.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Rozhinskaia L.Ia.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

List of references:

Neiroendokrinologiya. Klinicheskie ocherki. Pod red. E.I. Marovoi. Yaroslavl': DIA-press 1999: 81-144.
Pivonello R., Faggiano A., Lombardi G., Colao A. The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrin Metab Clin North Am 2005; 34: 2: 327-339.
Colao A., Pivonello R., Spiezia S. et al. Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 1999; 84: 8: 2664-2662.
Erbil Y., Ademoglu E., Ozbey N. et al. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome before and after surgery. World J Surg 2006; 30: 9: 1665-1671.
Marek J., Hána V., Krsek M. How corticoids, growth hormone and oestrogens influence lipids and atherosclerosis. Vnitr Lek 2007; 53: 4: 386-390.
Pivonello R., De Martino M.C., De Leo M. et al. Cushing's syndrome: aftermath of the cure. Arq Bras Endocrin Metab 2007; 51: 8: 1381-1381.
Tsuiki M., Tanabe A., Takagi S. et al. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome. Endocr J 2008; 55: 4: 737-745.
Albiger N., Testa R.M., Almoto B. et al. Patients with Cushing's syndrome have increased intimal media thickness at different vascular levels: comparison with a population matched for similar cardiovascular risk factors. Horm Metab Res 2006; 38: 6: 405-410.
Dovio A., Allasino B., Palmas E. et al. Increased osteoprotegerin levels in Cushing's syndrome are associated with an adverse cardiovascular risk profile. J Clin Endocrin Metab 2007; 92: 5: 1803-1888.
Faggiano A., Pivonello R., Spiezia S et al. Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 2003; 88(6): 2527-33
Mancini T., Kola B., Mantero F. et al. High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol (Oxf) 2004; 61: 6: 768-777.
Tauchmanovà L., Rossi R., Biondi B. et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrin Metab 2002; 87: 11: 4872-4878.
Whitworth J.A., Williamson P.M., Mangos G., Kelly J.J. Cardiovascular consequences of cortisol excess. Vasc Health Risk Manag 2005; 1: 4: 291-299.
Corrado E., Muratori I., Tantillo R. et al. Relationship between endothelial dysfunction, intima media thickness and cardiovascular risk factors in asymptomatic subjects. Int Angiol 2005; 24: 1: 52-58.
Zacharieva S., Atanassova I., Nachev E. et al. Markers of vascular function in hypertension due to Cushing's syndrome. Horm Metab Res 2005; 37: 1: 36-39.
Ermetici F., Malavazos A.E., Corbetta S. et al. Soluble adhesion molecules levels in patients with Cushing's syndrome before and after cure. J Endocrinol Invest. 2008; 31: 5: 389-392.
Dentali F., Romualdi E., Ageno W. The metabolic syndrome and the risk of thrombosis. Haematologica 2007; 92(3): 297-299
Kakafika A.I., Liberopoulos E.N., Karagiannis A. et al. Dyslipidaemia, hypercoagulability and the metabolic syndrome. Curr Vasc Pharmacol 2006; 4: 3: 175-183.
Semple P.L., Laws E.R. Jr. Complications in a contemporary series of patients who underwent transsphenoidal surgery for Cushing's disease. J Neurosurg 1999; 91: 2: 175-179.
Small M., Lowe G.D., Forbes C.D., Thomson J.A. Thromboembolic complications in Cushing's syndrome. Clin Endocrinol (Oxf) 1983; 19: 4: 503-511.
Sjöberg H.E., Blombäck M., Granberg P.O. Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome. Acta Med Scand 1976; 199: 1-2: 95-98.
Boscaro M., Sonino N., Scarda A. et al. Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrin Metab 2002; 87: 8: 3662-3666.
Dolgov V.V., Svirin P.V. Laboratornaya diagnostika narushenii gemostaza. M-Tver': Triada 2005: 44-49, 59-64.
Fred Dzh. Shiffman. Patofiziologiya sistemy krovi. Per. s angl. pod red. akad. Yu.V. Natochina. St-Peterburg: Nevskii dialekt 2001; 191-214, 253-269.
Lupinskaya Z.A. Endotelii sosudov - osnovnoi regulyator mestnogo krovotoka. Vestn KRSU 2003; 7
Ambrosi B., Sartorio A., Pizzocaro A. et al. Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes 2000; 108: 4: 294-298.
Patrassi G.M., Sartori M.T., Viero M.L. et al. The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 1992; 3: 6: 789-793.
Casonato A., Daidone V., Sartorello F. et al. Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br J Haematol 2008; 140: 2: 230-235.
Dal Bo Zanon R., Fornasiero L., Boscaro M. et al. Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state. Thromb Haemost 1982; 47: 2: 116-117.
Dal Bo Zanon R., Fornasiero L., Boscaro M. et al. Clotting changes in Cushing's syndrome: elevated factor VIII activity. Folia Haematol Int Mag Klin Morphol Blutforsch 1983; 110: 2: 268-277.
Fatti L.M., Bottasso B., Invitti C. et al. Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 2000; 23: 3: 145-150.
Kirilov G., Tomova A., Dakovska L. et al. Eur J Endocrinol. Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. 2003; 149: 6: 549-553.
Kristo C., Ueland T., Godang K. et al. Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. J Endocrinol Invest 2008; 31: 5: 400-405.
Casonato A., Pontara E., Boscaro M. et al. Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinol 1999; 10: 3: 145-151.
Prázný M., Jezková J., Horová E. et al. Impaired microvascular reactivity and endothelial function in patients with Cushing's syndrome: influence of arterial hypertension. Physiol Res 2008; 57: 1: 13-22.
Halleux C.M., Declerck P.J., Tran S.L. et al. Hormonal control of lasminogen activator inhibitor-1 gene expression and production in human adipose tissue: stimulation by glucocorticoids and inhibition by catecholamines. J Clin Endocrinol Metab 1999; 84: 11: 4097-4105.
Morange P.E., Aubert J., Peiretti F. et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999; 48: 4: 890-895.
Lordelo R.A., Mancini M.C., Cercato C., Halpern A. Hormonal axes in obesity: cause or effect? Arq Bras Endocrinol Metabol 2007; 51: 1: 34-41.
Walker B.R. Cortisol-cause and cure for metabolic syndrome? Diabet Med 2006; 23: 12: 1281-1288.
Iwasaki Y., Takayasu S., Nishiyama M. et al. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008; 285: 1-2: 10-8.
Góth M., Hubina E., Korbonits M. Correlations between the hypothalamo-pituitary-adrenal axis and the metabolic syndrome Orv Hetil 2005; 146: 2: 51-55.
Morton N.M., Densmore V., Wamil M. et al. A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action. Diabetes 2005; 54: 12: 3371-3378.
Alessi M.C., Juhan-Vague I. Metabolic syndrome, hemostasis and thrombosis. Thromb Haemost. 2008; 99: 6: 995-1000.
Kohler H.P. Insulin resistance syndrome: interaction with coagulation and fibrinolysis. Swiss Med Wkly 2002; 132: 19-20: 241-252.
Nieuwdorp M., Stroes E.S., Meijers J.C., Büller H. Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 2005; 5: 2: 155-159.
Palomo I., Alarcón M., Moore-Carrasco R., Argilés J.M. Hemostasis alterations in metabolic syndrome (review). Int J Mol Med 2006; 18: 5: 969-974.
Skurk T., Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 11: 1357-1364.
Van Guilder G.P., Hoetzer G.L., Greiner J.J. et al. Metabolic syndrome and endothelial fibrinolytic capacity in obese adults. Am J Physiol Regul Integr Comp Physiol 2008; 294: 1: R39-44.

Close metadata